REFERENCES
- Evans D. J., Taylor D. A., Zetterstrom O., Chung K. F., O'Connor B. J., Barnes P. J. A Comparison of Low-Dose Inhaled Budesonide Plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma. N. Engl. J. Med. 1997; 337: 1412–1418
- L'Enfant C., Khaltae N. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. Medical Communications Resources, Inc., U.S.A. 1995
- National Asthma Education and Prevention Program, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 97-4051. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, April 1997
- Banner K. H., Page C. P. Theophylline and Selective Phosphodiesterase Inhibitors as Anti-inflammatory Drugs in the Treatment of Bronchial Asthma. Eur. Respir. J. 1995; 8: 996–1000
- Rabe K. F., Dent G. Theophylline and Airway Inflammation. Clin. Exp. Allergy 1998; 28(suppl 3)35–41
- Baba K., Koishikawa I., Hattori T., Kamiya T., Yoshida K., Sekii T., Kobayashi T., Takagi K., Ueno K. Long-Term Monitoring of Serum Eosinophil Cationic Protein (ECP), Eosinophil Protein X (EPX) and Myeloperoxidase (MPO) in Adult Chronic Asthmatic Patients; Its Clinical Significance. Allerg. Immunol. 1996; 3: 62–70
- Baba K., Hattori T., Koishikawa I., Yoshida K., Kobayashi T., Takagi K. Serum Eosinophil Cationic Protein for Predicting the Prognosis of a Step Down in Inhaled Corticosteroid Therapy in Adult Chronic Asthmatics. J. Asthma 2000; 37: 399–408
- Baba K., Koishikawa T., Kobayashi T., Takgagi K., Ueno K. Long-Term Monitoring of Serum Eosinophil Cationic Protein and Myeloperoxidase in Asthmatic Patients. Am. J. Respir. Crit. Care Med. 1996; 153: A212
- Tsukioka K. Peak Expiratory Flow in Normal, Healthy Japanese Subjects. Kyowa-Kikaku, TokyoJapan 1995; 15–42
- Wenzel S. E., Schwartz L. B., Langmack E. L., Halliday J. L., Trudeau J. B., Gibbs R. L., Chu H. W. Evidence That Severe Asthma Can Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and Clinical Characteristics. Am. J. Respir. Crit. Care Med. 1999; 160: 1001–1008
- Adachi M., Minoguchi K., Mita S., Kokubu F., Suzuki H., Sano Y., Akiyama K., Yasuhara H. Effect of Slow-Release Theophylline on Airway Inflammation in Bronchial Asthma. Arerugi 1998; 47: 734–743
- Sullivan P., Bekir S., Jaffar Z., Page C., Jeffery P., Costelo J. Anti-inflammatory Effects of Low-Dose Oral Theophylline in Atopic Asthma. Lancet 1994; 343: 1006–1008
- Ohta K., Sawamoto S., Nakajima M., Kubota S., Tanaka Y., Miyasaka T., Nagai A., Hirai K., Mano K., Miyashita H. The Prolonged Survival of Human Eosinophils with Interleukin-5 and Its Inhibition by Theophylline Via Apoptosis. Clin. Exp. Allergy 1996; 26(suppl 2)10–15
- Tohda Y., Muraki M., Iwanaga T., Kubo H., Fukuoka M., Nakajima S. The Effect of Theophylline on Blood and Sputum Eosinophils and ECP in Patients with Bronchial Asthma. Int. J. Immunopharmacol. 1998; 20: 173–181
- Kidney J., Dominguez M., Taylor P. M., Rose M., Chung K. F., Barnes P. J. Immunomodulation by Theophylline in Asthma. Demonstration by Withdrawal of Therapy. Am. J. Respir. Crit. Care Med. 1995; 151: 1907–1914